OptimizeRx (OPRX) Net Equity Issued and Repurchased (2014 - 2021)

OptimizeRx has disclosed Net Equity Issued and Repurchased across 6 years of filings, most recently posting $70.7 million for Q1 2021.

• In Q1 2021, Net Equity Issued and Repurchased changed N/A year-over-year to $70.7 million; the TTM figure through Dec 2021 stood at $70.7 million (changed N/A YoY), while the FY2021 annual figure was $70.7 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased came in at $70.7 million for Q1 2021 at OptimizeRx, up from $1.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $70.7 million in Q1 2021 to a low of -$1.3 million in Q4 2018.
• Average Net Equity Issued and Repurchased over 4 years is $11.7 million, with a median of $328673.5 recorded in 2018.
• Year-over-year, Net Equity Issued and Repurchased sank 54.25% in 2019 and soared 406.53% in 2020.
• Over 4 years, Net Equity Issued and Repurchased stood at -$1.3 million in 2018, then rose by 17.45% to -$1.1 million in 2019, then surged by 198.03% to $1.0 million in 2020, then soared by 6662.2% to $70.7 million in 2021.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $70.7 million in Q1 2021, $1.0 million in Q3 2020, and -$1.1 million in Q4 2019.